A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumor
Interventions: DRUG: BDTX-189
Sponsor: Black Diamond Therapeutics, Inc.